GLP-1 riches are being repurposed to prevent infections.
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Tiffany Herring/Axios
Eli Lilly on Tuesday said that it has agreed to pay up to $3.8 billion in cash to buy three vaccine developers: Curevo, LimmaTech, and Vaccine Co.
Why it matters: GLP-1 riches are being repurposed to prevent infections.
Lilly dives into vaccine research with 3 biotech buyouts
Eli Lilly acquires three vaccine developers for $3.8 billion
Three vaccine biotechs to be bought by Lilly for up to $3.8B
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Eli Lilly to buy three small vaccine developers
Eli Lilly comprará 3 empresas fabricantes de vacunas por casi 4 mil mdd; ampliará investigación de enfermedades infecciosas | El Universal
What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)
Five biotech news updates to stay on top of today
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an…
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss…
Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious…
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling…
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
